MediciNova, Inc. (MNOV)

[Minding]

One view, technical for the most part.

Kind regards,
Minding

---------------

From http://www.financialmagazin.com/what-will-happen-to-medicinova-inc-next-the-stock-just-reaches-52-week-low/

What Will Happen to MediciNova, Inc. Next? The Stock Just Reaches 52-Week Low

The stock of MediciNova, Inc. (MNOV) hit a new 52-week low and has $2.05 target or 28.00% below today’s $2.85 share price. The 8 months bearish chart indicates high risk for the $84.89 million company. The 1-year low was reported on Oct, 21 by Barchart.com. If the $2.05 price target is reached, the company will be worth $23.77M less.

The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. The stock is up 2.15% or $0.06 after the news, hitting $2.85 per share. About 107,871 shares traded hands or 41.33% up from the average. MediciNova, Inc. (NASDAQ:MNOV) has declined 18.42% since March 18, 2015 and is downtrending. It has underperformed by 15.15% the S&P500.

Analysts await MediciNova, Inc. (NASDAQ:MNOV) to reports earnings on October, 29. After $-0.09 actual EPS reported by MediciNova, Inc. for the previous quarter, Wall Street now forecasts 11.11% negative EPS growth.

According to Zacks, “MEDICINOVA, INC. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova’s pipeline includes six clinical-stage compounds for the treatment of status asthmaticus, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova will seek to monetize its other product candidates at key value inflection points.”

The institutional sentiment increased to 1 in Q2 2015. Its up 0.55, from 0.45 in 2015Q1. The ratio increased, as 5 funds sold all MediciNova, Inc. shares owned while 4 reduced positions. 2 funds bought stakes while 7 increased positions. They now own 2.52 million shares or 0.18% more from 2.51 million shares in 2015Q1.

Essex Woodlands Health Ventures Inc. holds 0.83% of its portfolio in MediciNova, Inc. for 1.17 million shares. Bridgeway Capital Management Inc owns 66,592 shares or 0.01% of their US portfolio. Moreover, Bank Of America Corp De has 0% invested in the company for 3,020 shares. The United Kingdom-based Barclays Plc has invested 0% in the stock. Blackrock Fund Advisors, a California-based fund reported 60,997 shares.